Predictors of major neurologic improvement after thrombolysis in acute stroke

Neurology

Volumn 65, Issue 8, 2005, Pages 1169-1174

  Saposnik, Gustavo ^a,b   Di Legge, Silvia ^a   Webster, Fiona ^a   Hachinski, Vladimir ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; GLUCOSE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREDICTION; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

EID: 27144486883     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000180687.75907.4b     Document Type: Article

References (29)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Haley EC, Jr., Lewandowski C, Tilley BC. Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med 1997; 30:676-682.
3. Brown DL, Johnston KC, Wagner DP, Haley EC, Jr. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147-150.
4. Brandt T, von Kummer R, Muller-Kuppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996;27:875-881.
5. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821-2827.
6. Alexandrov AV, Demchuk AM, Felberg RA, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring. Stroke 2000;31:610-614.
7. Demchuk AM, Burgin WS, Christou I, et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93.
8. Felberg RA, Okon NJ, El-Mitwalli A, Burgin WS, Grotta JC, Alexandrov AV. Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke 2002;33:1301-1307.
9. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation 2001;103:2897-2902.
10. Johnston KC, Connors AF, Jr., Wagner DP, Knaus WA, Wang X, Haley EC, Jr. A predictive risk model for outcomes of ischemic stroke. Stroke 2000;31:448-455.
11. Marier JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55:1649-1655.
12. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005;36:62-65.
13. Merino JG, Silver B, Wong E, et al. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke 2002;33: 141-146.
14. Saposnik G, Young B, Silver B, et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA 2004;292:1839-1844.
15. Fiorelli M, Alperovitch A, Argentino C, et al. Prediction of long-term outcome in the early hours following acute ischemic stroke. Italian Acute Stroke Study Group. Arch Neurol 1995;52:250-255.
16. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-2125.
17. Glader EL, Stegmayr B, Norrving B, et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 2003;34:1970-1975.
18. Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute stroke. Stroke 2003;34:1581-1585.
19. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-1838.
20. Censori B, Camerlingo M, Casto L, et al. Prognostic factors in first-ever stroke in the carotid artery territory seen within 6 hours after onset. Stroke 1993;24:532-535.
21. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547-2553.
22. Caplan LR. Treatment of acute stroke: still struggling. JAMA 2004;292: 1883-1885.
23. Urbinelli R, Bolard P, Lemesle M, et al. Stroke patterns in cardio-embolic infarction in a population-based study. Neurol Res 2001;23: 309-314.
24. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002;59: 669-674.
25. Pulsinelli WA, Levy DE, Duffy TE. Regional cerebral blood flow and glucose metabolism, following transient forebrain ischemia. Ann Neurol 1982;11:499-502.
26. Yip PK, He YY, Hsu CY, Garg N, Marangos P, Hogan EL. Effect of plasma glucose on infarct size in focal cerebral ischemia-reperfusion. Neurology 1991;41:899-905.
27. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32: 1832-1840.
28. Martinez-Vila E, Irimia P. The cost of stroke. Cerebrovasc Dis. 2004;17 suppl 1:124-129.
29. Saposnik G, Webster F, O'Callaghan C, Hachinski V. Optimizing discharge planning: clinical predictors of longer stay after recombinant tissue plasminogen activator for acute stroke. Stroke 2005;36:147-150.